NEW YORK (GenomeWeb News) – Bruker BioSciences today said that its non-affiliated stockholders have approved the acquisition of Bruker BioSpin.
Bruker’s $914 million acquisition of sister company BioSpin cleared the US antitrust period last month. BioSpin is 100 percent owned by members of the Laukien family, who also own 52 percent of Bruker BioSciences. Following completion of the deal, the combined firm will be renamed Bruker Corporation and 60 percent of its shares will be held by the Laukien family.
In addition to approving the acquisition, shareholders approved amendments to the firm’s certificate of incorporation including the name change.
The firm also said today that Tony Keller, executive chairman and former CEO of BioSpin, and Dirk Laukien, president of Bruker Optics, were elected to serve on Bruker’s board of directors.